|

Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma

RECRUITINGEarly 1Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Actively Recruiting
PhaseEarly 1
SponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS
Started2024-11-25
Est. completion2026-08-31
Eligibility
Age0 Years – 18 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06959979

Summary

Medulloblastoma (MB), a rare yet critical pediatric brain tumor, is divided into 4 molecular subgroups (WNT, SHH, Group 3, Group 4), each with distinct genetic profiles. Despite diagnostic and therapeutic advances, neurotoxicity from standard treatments (resection, radiotherapy, chemotherapy) and the need for long-term care remain challenges. CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib), approved for breast cancer, show potential in other tumors, but their efficacy in MB is unclear. Treatment resistance is a concern. This project aims to identify genetic markers of sensitivity to CDK4/6 inhibitors in MB, to improve therapies and overcome resistance.

Eligibility

Age: 0 Years – 18 YearsHealthy volunteers accepted
Inclusion Criteria:

* All patients affected by Medulloblastoma operated on at the Pediatric Neurosurgery Unit during their pediatric age will be elected to take part to the study

Conditions2

CancerMedulloblastoma, Childhood

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.